87 results found | searching for "Partnership"

2 3 4 5 6 7 8 9 Next Last 
  • jameshebrew
  • The ADC contract manufacturing market is projected to grow at a CAGR of more than 13% till 2035, claims Roots Analysis Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers. London Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings. In order to mitigate the challenges associated with Antibody Drug Conjugate manufacturing, around 70-80% of the therapeutics developers prefer to outsource their operations to contract manufacturing organizations (CMOs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/218/request-sample.html Key Market Insights Presently, more than 30 players claim to offer ADC contract manufacturing services This segment of the industry is dominated by the presence of large (more than 501 employees) and mid-sized (51-500 employees) players, which collectively represent more than 80% of the total contract manufacturers in this domain. In addition, around15% firms were established post 2010. More than 84 expansions were reported in this industry, during 2012-2021 Of the total, 57% instances were focused on enhancing dedicated capabilities and capacities, followed by those carried out for the expansion / establishment of manufacturing facilities (42%). Partnership activity in this domain has increased at a CAGR of over 16%, during 2016- 2021 Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (18%), followed by product development agreements (16%) and research agreements (15%). Further, most of the deals were inked by players based in Europe (46%). Global, installed ADC contract manufacturing capacity is currently estimated to be close to 33 Kilograms The maximum share of the current installed capacity is expected to be captured by large players. Moreover, close to 37% of the installed manufacturing capacity is available in the Asia-Pacific region. 140,200+ patients have been enrolled in over 714 clinical trials, worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 21%, in the past three years. Of the total number of trials, close to 47% of the studies are recruiting patients, while 30% have been completed. Global demand for ADC contract manufacturing is anticipated to grow at a CAGR of 13%, during 2022-2035 The commercial demand for ADC therapeutics is projected to increase at a CAGR of 22%. Further, the clinical demand for ADC therapeutics in phase III trials is projected to increase at a CAGR of 10%. The market is anticipated to grow at a CAGR of nearly 13%, during the period 2022-2035 In terms of type of cancer, ADC therapeutics targeting solid tumors (48%) are anticipated to capture the highest share; this trend is unlikely to change in the foreseen future. Further, based on type of antibody isotype, majority of the revenue share (90%) of the overall market is likely to be driven by IgG1 antibodies. While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information. For additional details please visit https://www.rootsanalysis.com/reports/view_document/adc-contract-manufacturing-market/218.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The taste masking market is anticipated to grow at a steady pace till 2035, claims Roots Analysis Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years. London Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings. The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production. Key Market Insights Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%). Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions). Partnership activity in this field has grown significantly between 2018 and 2021 The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%). More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017 Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%). North America is anticipated to capture larger share of the market by 2035 The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:  Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)  David Tisi (Director of Technical Operations, Senopsys)  Brandon Keener (Business Development Associate, Adare Pharma Solutions) For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The Artificial Intelligence in Oncology market is anticipated to grow at a CAGR of 54% claims Roots Analysis The success of currently employed artificial intelligence (AI) solutions has encouraged researchers to explore the potential of such technologies in the healthcare sector, with its prime focus being oncology, to enable the treatment of several prevalent malignancies. London Roots Analysis has announced the addition of “Artificial Intelligence in Oncology Market, 2022-2035” report to its list of offerings. Several AI technologies demonstrating the potential to diagnose precancerous lesions are expected to be capable of reducing mortality rates by improving detection accuracy, speed and providing assistance in clinical decision-making. This is further expected to result in better clinical outcomes. Overall, this domain is anticipated to gain significant traction, in the foreseen future. Key Market Insights Over 76 companies claim to be engaged in the development of AI in oncology software solutions The AI in diagnostics market is dominated by companies based in North America, primarily in the US; of these, majority were established post 2010 and are small firms. Majority of the companies in this domain offer software solutions to hospitals (52%). Nearly 2,770 patents have been filed / granted for AI based software solutions targeting oncology Reflecting the increasing research efforts of several industry players engaged in this domain, around 60% of the patents focused on the AI in oncology domain were filed / granted in North America, primarily in the US. It is also worth noting that the maximum patents were filed (69%) by non-academic players. Partnership activity in this market has increased at a CAGR of 36% over the past five years Technology integration agreements emerged as the most popular type of partnership model adopted by AI in oncology software solution providers, representing over 30% of the total instances. It is worth mentioning that 41% of the partnerships in this domain were inked in 2021. USD 5.9+ billion has been invested by both private and public investors, since 2017 The maximum funding amount was raised through venture capital (66%), grants (11%) and seed funding (8%), during the period 2017-2022. Interestingly, around 86% of the funding instances were reported by players based in the US. Europe is anticipated to capture over 30% of the global market share in 2035 In terms of cancer, the AI in oncology market for solid malignancies is likely to capture the maximum share (33%), followed by the share captured by breast cancer (30%), and this trend is unlikely to change in the foreseen future as well. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of AI in oncology-based software solutions?  Which type of end-users are primarily employing AI in oncology-based software solutions in their regular workflow?  What kind of partnership models are most commonly being adopted by stakeholders engaged in this domain?  What is the trend for capital investments in this domain?  What are the key strategies that can be implemented by emerging players / start-ups to enter into this highly competitive market?  What is the focus area of big pharma players in this domain?  Which companies are actively filing patents to drive innovation in the field of AI in oncology?  What are the key challenges associated within this domain? The financial opportunity within the AI in oncology market has been analyzed across the following segments:  Type of Cancer  Solid Malignancies  Breast Cancer  Lung Cancer  Prostate Cancer  Colorectal Cancer  Brain Tumor  Others  Type of End-User  Hospitals  Pharma Companies  Research Institutes  Others  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the world The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:  Jon DeVries (Chief Executive Officer, Mirada Medical)  Piotr Krajewski (Chief Executive Officer, CancerCenter.AI)  Christian Vestergaard Kaltoft (Chief Executive Officer, Visiopharm)  David Wilson (Vice President, Marketing and Communications, Enlitic)  Emily Salerno (Commercial Strategy and Operations Lead, Nucleai) The research includes detailed list of platforms being developed by key players (some of them are listed below); the report features an overview of the platform, details related to the AI technology employed, oncological indication targeted and information related to the type of platform (cloud-based, on-site).  Ibex Medical Analytics  Niramai  Optellum  Tempus Labs  Paige  Kheiron Medical Technologies For additional details, please visit https://www.rootsanalysis.com/reports/ai-in-oncology-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The human microbiome market is anticipated to grow at a CAGR of 24% till 2035, claims Roots Analysis With the increasing concept of precision medicine, several scientists have demonstrated interest in the therapeutic manipulation of human microbiome (commonly gut bacteria) for the treatment of a wide range of disease indications. Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings. The microbiome-based therapies pipeline features six drugs in phase III clinical development, over 200 candidates in other clinical and preclinical stages of development along with more than 60 diagnostics and screening / profiling tests that are commercialized for the detection of various diseases. However, the current microbiome market is driven by the fecal microbiota therapies approved by the FDA, particularly for the recurrent CDI and the commercialized diagnostic tests available to the patients. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. Key Market Insights Over 230 drug candidates are currently being developed by more than 70 drug developers Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders. More than 75 diagnostics and screening / profiling test are available / under development Of these, around 80% of the tests are available in the market, while rest are under development. More than 40 companies are engaged in providing these tests; these are primarily based in North America (45%) and Europe (39%). It is worth highlighting that majority (68%) of the players are small companies. FMTs are the only commercially available microbiome therapies approved by the FDA These therapies are primarily used for the treatment of recurrent Clostridium difficile infection (rCDIs). It is worth mentioning that more than 400 trials have been registered for evaluating these therapies for a wide range of indications. Partnership activity in this domain has increased at a CAGR of 26%, between 2017 and 2021 Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period. More than USD 1 billion has been invested by both private and public investors, since 2017 Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million. Outsourcing has become an integral part of the microbiome and live biotherapeutics development process Presently, over 25 service providers claim to offer a multitude of contract manufacturing services for microbiome and live biotherapeutic products. It is worth noting that close to 10 firms were established post 2010 and around 45% of the players are located in Europe. Microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035 As late-stage therapeutics will get approved by the FDA in the foreseen future, the microbiome therapeutics market is likely to grow at an annualized rate of 37% till 2035. It is worth mentioning that microbiome diagnostics is likely to capture 20% of the total microbiome market share by 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/281/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of microbiome therapeutics?  Which are the key microbiome based drugs being developed across various stages of development?  Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?  Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?  Which types of partnership models are commonly adopted by industry stakeholders?  Who are the key investors in the field of human microbiome therapeutics and diagnostics?  What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?  What is the role of various start-ups engaged in developing human microbiome therapeutics?  Which are the most commonly targeted therapeutic indications for which microbiome therapeutics are being developed?  What are the various steps involved in the manufacturing of microbiome therapeutics?  What are the key considerations for selecting a CMO / CRO for manufacturing of microbiome therapeutics?  What are the various algorithms / tools used to analyze data generated from microbiome research?  How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?  What are the various non-pharma applications of microbiome products? The financial opportunity within the human microbiome therapeutics market has been analyzed across the following segments:  Type of Product  Probiotic Drugs  Other Drugs  Target Indication  Recurrent C. difficile Infection  Necrotizing Enterocolitis  Primary Hyperoxaluria  Graft versus Host Disease  Therapeutic Area  Infectious Diseases  Digestive and GI Disorders  Rare Disorders  Route of Administration  Oral Route  Rectal Route  Type of Formulation  Capsules  Suspensions  Enemas  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the human microbiome diagnostics and screening / profiling tests market has been analyzed across the following segments:  Target Indication  Irritable Bowel Syndrome  Inflammatory Bowel Disease  Colorectal Cancer  Diabetes Mellitus  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the fecal microbiota therapies market has been analyzed across the following segments:  Key Geographical Regions  North America  Europe  Asia Pacific The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the growth of the human microbiome market. It includes detailed transcripts of the discussions held with the senior representatives of the stakeholder firms, including:  Charlie Badham (Senior Manager, Corporate Development, 4D Pharma)  Nicholas Monsul (Co-founder and Chairman, Quorum Innovations)  Alicia Scheffer (Chief Executive Officer, Floragraph)  Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)  Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)  Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)  Assaf Oron (Chief Business Officer, BiomX)  Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)  Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)  Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics)  Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)  James Burges (Ex-Co-founder and Vice President of Innovation, OpenBiome)  Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)  JP Benya (Ex-Vice President, Operations, Assembly Biosciences)  Lee Jones (President and Chief Executive Officer, Rebiotix)  Mark Heiman (Ex-Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)  Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra) The report also includes detailed profiles of the companies (listed below) engaged in developing microbiome therapeutics, diagnostics and screening / profiling test; each profile features an overview of the company, its financial information (if available), details on its product portfolio, recent developments, and an informed future outlook.  4D Pharma  Biosotia Microbiomics  DNA Genotek  Finch Therapeutics  GoodGut  Infant Bacterial Therapeutics  Invivo Healthcare  MaaT Pharma  OxThera  Qu Biologics  Rebiotix  Seres Therapeutics  Servatus  Shoreline Biome For additional details, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis [more]
  • jameshebrew
  • The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035, claims Roots Analysis An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries. Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings. Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding. Key Market Insights Currently, around 120 needlestick safety injection devices are available in the market More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections. Over 50 companies claim to develop needlestick safety injection devices, worldwide Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%). Partnership activity within this field has grown significantly between 2020 and 2022 Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions. Over USD 260 million has been invested by both private and public investors, since 2016 Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain. Close to 20 global events were organized in the past couple of years in this industry Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries. More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018 Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes. North America and Europe are anticipated to capture more than 75% of the market by 2035 Growth in this domain is anticipated to be primarily driven by the rising cases of needlestick injuries amongst the healthcare workers. The Asia-Pacific needlestick safety injection devices market currently accounts for more than 20% of the global market. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/needlestick-safety-market/request-sample.html Key Questions Answered  Who are the leading needlestick safety injection devices developers?  Which are the popular types of safety injection devices available in this market?  What are the key challenges faced by stakeholders engaged in the development of needlestick safety injection devices?  What types of partnership models are commonly being adopted by stakeholders in this industry?  How has the intellectual property landscape of needlestick safety injection devices developers evolved over the years?  Which factors are likely to influence the evolution of this market?  How is the current and future market opportunity likely to be distributed across key market segments? The research also includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.  B. Braun  BD  Gerresheimer  HTL-STREFA  Nipro Europe Group Companies  SOL-MILLENNIUM Medical Group For additional details, please visit https://www.rootsanalysis.com/reports/needlestick-safety-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035, claims Roots Analysis Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products. Key Questions Answered  Who are the leading players offering services for the development of companion diagnostics?  Which are the key geographies where companion diagnostics development service providers are located?  Which analytical techniques are used by the service providers engaged companion diagnostics development services market?  Who are the leading companion diagnostics developers?  Which biomarkers are most commonly targeted by the marketed products / investigational programs?  Which partnership models are commonly adopted by stakeholders offering companion diagnostics development services?  Which drug developers are most likely to partner with the service providers to seek their expertise?  What are the key value drivers of the merger and acquisition activity within companion diagnostics development services market?  Which biomarker-focused targeted drugs developed by big pharmaceutical companies are likely to be administered with companion diagnostics?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the companion diagnostics development services market has been analyzed across the following segments:  Type of Service Offered  Feasibility Studies  Assay Development  Analytical Validation  Clinical Validation  Manufacturing  Type of Technique Used  NGS  PCR  ICH / ISH  Liquid Biopsy  Others  Therapeutic Areas  Oncological  Non-oncological  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:  Mike Klein (Chief Executive Officer, Genomenon)  Mark Kiel (Founder and Chief Scientific Officer, Genomenon)  Candace Chapman (Vice President of Marketing, Genomenon)  Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations)  Paul Kortschak (Former Senior Vice President, Novodiax)  Pablo Ortiz (Chief Executive officer, OWL Metabolomics)  Lawrence Weiss (Former Chief Scientific Officer, NeoGenomics Laboratories) The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, and an informed future outlook.  Almac Diagnostic Services  BGI Genomics  Biocartis  Cerba Research  Geneuity Clinical Research Services  Interpace Biosciences  Labcorp (formerly known as Covance)  MEDICAL & BIOLOGICAL LABORATORIES (MBL)  MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)  MLM Medical Labs  Novogene  Q2 Solutions  Quest Diagnostics  ResearchDx For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • KPaulIndustrial
  • When you buy from a Service-Disabled Veteran-Owned small business, you are helping America’s Armed Services heroes. Disabled in the line of duty, you provide gainful employment to those who have dedicated their all to the country. KPaul Industrial has been an industrial supply USA and product distributor since 2006. We have paired with the greatest players in the market to provide you with top-of-the-line products at the best prices, while always working to expand our partnerships and product offerings. https://kpaulindustrial.com/ Address --- 5605 W 74th St, Indianapolis, IN 46278, United States EMAIL- sales@kpaul.com Phone number - +1 317-243-1750 Social links - https://www.facebook.com/kpaulindustrial/ https://twitter.com/kpaulcorp Other Links https://kpaulindustrial.com/industrial-supplies.html [more]
  • manishwts
  • ‘Heal in India’ initiative: Public-Private Partnership gives Boost to Medical Tourism https://gomedii1.medium.com/heal-in-india-initiative-public-private-partnership-gives-boost-to-medical-tourism-e181a1dcc257 [more]
  • jasoncohen08
  • Jason Cohen Pittsburgh | https://ocnjdaily.com/jason-cohen-nexus-real-estate-discusses-renovation-projects-add-value-home-resale/ | Address: 2275 Swallow Hill Rd, Pittsburgh, PA 15220 | Phone: (412) 455-5600 | Jason Cohen of Nexus Real Estate in Pittsburgh, PA is a real estate reclamation expert who has developed a portfolio of dozens of rental assets including commercial and residential properties. Jason Cohen is the founder of Nexus Real Estate and also Jason Cohen Pittsburgh, which is a resource for clients in the real estate market. Mr. Cohen can be contacted for partnership opportunities through the Jason Cohen Nexus website. #Real Estate #Jason Cohen Nexus Real Estate
  • rsolar
  • solar installers in adelaide solar system in adelaide We have established strong trading partnerships with fine solar products over the years, and our solar panels Adelaide prices are extremely cost-effective. We are recognized as the best solar system suppliers and solar installers in Adelaide and the surrounding areas. for more - https://revolutionarysolar.com.au/solar/solar-installers-in-adelaide [more]
2 3 4 5 6 7 8 9 Next Last